Back to discover
Disease

Anaphylaxis

Late-stage therapeutic developmentEmerging research
MeSHAnaphylaxis
1
Publications
13
Clinical trials
2008
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Approval: Eurneffy (EMA)

Regulatory2024-08-22EMA

Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.

Research2008-03-01The New England journal of medicine

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 4 clinical trials expected to report results, the earliest in Q4 2026.
Upcoming Milestones
Major developments
Upcoming trial readoutHigh impact
A First-in-Human, Ascending Dose, Open-label, Multicenter Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of UKK-0018 in Peanut Allergic Individuals
Results expected Q1 20272026-06-25
Upcoming trial readoutImportant
Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
Results expected Q3 20282026-05-26
Clinical Milestones5View
Results expected 4
Recently completed 1
Activity timeline5

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Epinephrineapproved

Approval — Eurneffy is indicated in the emergency treatment of allergic reactions (anaphylaxis) due… (2024)

Clinical trials

12 sponsors · 2 new · 0 completed in the last 12 months (net +2)

The current development programme across all trial phases.

Clinical programme
13
All trials
6
Active
1
Late-stage
6
Completed
Recruiting

A First-in-Human, Ascending Dose, Open-label, Multicenter Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of UKK-0018 in Peanut Allergic Individuals

Phase 1/2 · Recruiting · Ukko Inc

Use of Dexamethasone in Prevention of the Second Phase or a Biphasic Reaction of Anaphylaxis

Phase 1 · Recruiting · Hamad Medical Corporation

Evaluation of Emergency Medication in Children With Food Allergies: a Prospective, Randomized Clinical Multicenter Study Comparing Antihistamines Versus Antihistamines Plus Steroids in a Controlled Setting of Oral Food Challenges in Children.

Phase 4 · Recruiting · Johannes Trueck

Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

Phase 2 · Recruiting · Massachusetts General Hospital

A Phase II Trial to Evaluate the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients

Phase 2 · Recruiting · Rima Rachid
Recently completed

A Study to Compare the Bioavailability of Epinephrine Following a Single Nasal Dose of FMXIN002 Microspheres Powder 3.6mg, and 4mg With EpiPen 0.3mg Intramuscular Injection in Healthy Adults

Phase 1/2 · Completed · Nasus Pharma

Bioavailability Comparison of Epinephrine Following a Single Nasal Dose of Microspheres Powder With Epinephrine Intramuscular Injection in Adults With Seasonal Allergic Rhinitis With and Without Nasal Allergen Challenge

Phase 1 · Completed · Nasus Pharma

Inhibition of Anaphylaxis by Ibrutinib

Phase 2 · Completed · Ann & Robert H Lurie Children's Hospital of Chicago

An Single-dose, Open Label, Randomized Cross-over Study to Explore the Pharmacokinetics and Pharmacodynamics of Epinephrine in Healthy Male and Female Subjects With Different Skin to Muscle Depth (STMD)

Phase 1 · Completed · Bausch & Lomb Incorporated

A Randomized Double-Blinded, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis

Phase 2 · Completed · National Institute of Allergy and Infectious Diseases (NIAID)

Comparison of Absorption of Epinephrine Into the Circulation After Epinephrine Intranasal Spray Administration and After Intramuscular Injection

N/A · Completed · Siriraj Hospital

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2024emaApproval — Epinephrine· Eurneffy is indicated in the emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products and other allergens as well as idiopathic or exercise induced anaphylaxis. Treatment is indicated for adults and children aged 4 years and over with a body weight of 15 kg or more. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Most influential

Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.

The New England journal of medicine · 2008 · 1,046 cites
Recent publications

Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.

The New England journal of medicine · 2008 · 1,046 cites
Leading journals1
  • The New England journal of medicine1
Leading researchers8
  • Berlin J1
  • Chan E1
  • Chung CH1
  • Gold D1
  • Hatley T1
  • Hicklin DJ1
  • Hosen J1
  • Le QT1
Affiliations (unnormalised)1
  • Vanderbilt University School of Medicine1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

An acute hypersensitivity reaction due to exposure to a previously encountered ANTIGEN. The reaction may include rapidly progressing URTICARIA, respiratory distress, vascular collapse, systemic SHOCK, and death.

Identifiers
MeSHAnaphylaxis
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.